论文部分内容阅读
2013年3月至2015年3月我科收治的120例早期糖尿病肾病患者为研究对象,平均分为观察组和对照组。对照组根据患者症状采用常规对症治疗,观察组在对照组的基础上另加用前列地尔治疗,比较治疗前后两组患者相关肾功能指标及血糖指标。结果经治疗后两组患者尿素氮、尿蛋白排泄率、糖化血红蛋白及血糖水平较治疗前均明显降低(P<0.05);治疗后两组患者在血肌酐、糖化血红蛋白及血糖水平方面比较无显著性差异(P>0.05),治疗后观察组尿素氮及尿蛋白排泄率水平均明显低于治疗后的对照组(P<0.05),差异具有统计学意义。结论合理应用前列地尔治疗可降低早期糖尿病肾病患者持续微量白蛋白尿水平,改善肾功能不全,对延缓肾脏损害,防治终末期肾衰竭有重要意义。
From March 2013 to March 2015, 120 patients with early stage diabetic nephropathy admitted in our department were divided into observation group and control group. Control group according to the symptoms of patients with conventional symptomatic treatment, the observation group on the basis of the control group plus alprostadil treatment, compared before and after treatment, the two groups of patients with renal function indicators and blood glucose indicators. Results After treatment, the urinary nitrogen and urinary protein excretion rate, glycosylated hemoglobin and blood glucose level in both groups were significantly lower than those before treatment (P <0.05); after treatment, there was no significant difference in serum creatinine, HbA1c and blood glucose between the two groups (P> 0.05). After treatment, the levels of urea nitrogen and urinary protein excretion in the observation group were significantly lower than those in the control group after treatment (P <0.05), and the difference was statistically significant. Conclusion The rational application of alprostadil therapy can reduce persistent albuminuria in patients with early stage diabetic nephropathy and improve renal insufficiency, which is of great significance for delaying renal damage and preventing and treating end-stage renal failure.